CUPRIC CHLORIDE
Cupric chloride injection 0.4 mg/mL is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Details
- Status
- Prescription
- First Approved
- 2022-10-31
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
CUPRIC CHLORIDE Approval History
What CUPRIC CHLORIDE Treats
3 FDA approvalsOriginally approved for its first indication in 2022 . Covers 3 distinct patient populations.
- Other (3)
Other
(3 approvals)- • Approved indication (Oct 2022)Letter
- • Approved indication (Apr 2024)
- • Approved indication (Jan 2026) New
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CUPRIC CHLORIDE FDA Label Details
Indications & Usage
Cupric chloride injection 0.4 mg/mL is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Looking for the branded version?
CUPRIC CHLORIDE IN PLASTIC CONTAINER
Full clinical data, patents, trials, and competitive landscape for cupric chloride.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.